Active Clinical Trials

The Division of Infectious Diseases and Travel Medicine is currently participating and enrolling patients into the following trials: 

  1. GS-US-200-4334: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV
  2. MK8591A-017: A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy
  3. MK8591A-019: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL
  4. TJ003234COV201: A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)
  5. INCB18424-369: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
  6. CA42481: A Phase II, Open-Label, Randomized, Multicenter Study To Investigate the Pharmacodynamics, Pharmacokinetics, Safety and efficacy of 8mg/kg or 4mg/kg Intravenous Tocilizumab in Patients with moderate to severe COVID-19 Pneumonia
  7. BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen
  8. COVID-19–associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
  9. 20-0006: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
  10. WA42511: A Phase III, Randomized, Double-Blind, Multicenter Study To Evaluate The Efficacy And Safety Of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo In Hospitalized Patients With Severe Covid-19 Pneumonia
  11. J2W-MC-PYAB: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants with Mild to Moderate COVID-19 Illness
  12. AI438047/205888: A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
  13. Development of a City-Wide “DC Cohort” of HIV-Infected Persons in Care in the District of Columbia the “DC Cohort”
  14. A5332 FINAL Version 5.0, 04/01/19 Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)
  15. MK1439A-021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
  16. MK1439A-024: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  17. AIC316-03-II-01: A randomized, open label, multi center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults (PRIOH-1)
  18. GS-US-420-3902: A Phase 1b Randomized, Blinded, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-9722, Administered Alone or in Combination with Vesatolimod, in Virologically Suppressed HIV-1 Infected Subjects on ART
  19. A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482
  20. SALSA/208090: A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed
  21. Strategic Timing of AntiRetroviral Treatment (START)
  22. ATLAS-2M/207966: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults
  23. SERES-012: ECOSPOR III: A Phase 3 Multicenter, RandomizEd, Double Blind, PlaceboCOntrolled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI)
  24. SERES-013: ECOSPOR IV: An Open-Label Extension Of Study SERES-012 Evaluating SER-109 In Adult Subjects With Recurrent Clostridium Difficile Infection (RCDI)
  25. Global TravEpiNet
  26. MDA 2013-0039: A Phase 3, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
  27. A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection
  28. The utility of the Filmarray multiplex assay respiratory virus panel (RVP) in the diagnosis and management of respiratory tract infections in hospitalized patients
  29. Risk Factors for COVID-19 in hospitalized patients
  30. Epidemiology and antibiotic susceptibility of Multidrug Resistant Organisms (MDROs) and Carbipenem-Resistant Enterobacteriaceae (CRE) colonization and infection among acute care hospitalized patients
  31. STOP-COVID: Study of the Treatment and Outcomes in critically ill Patients with COVID-19
  32. Secondary Attack Rate of COVID-19 Among Exposed Healthcare Personnel in the District of Columbia
  33. Iatrogenic QTc Prolongation in treatment of COVID-19
  34. Multi-Drug Resistant Organism (MDRO) Infections in Liver Transplant Recipients in the 30 Day Post-Operative Period: A Retrospective Study
  35. Multi-Drug Resistant Organism (MDRO) Infections in Kidney and Kidney-Pancreas Transplant Recipients in the 30 Day Post-Operative Period: A Retrospective Study
  36. Pharmacoepidemiology of Ceftazidime-Avibactam: A Multicenter Cohort Study for Clinical Validation of Real World Practice Patterns and Outcomes
  37. Manifestations, Treatment, And Outcomes of COVID-19 in Solid Organ Transplant Patients
  38. SARS-CoV-2 infection and its impact in endothelial inflammation and repair in patients diagnosed with COVID-19
  39. Characterizing Infections in Intestinal Transplant Patients, A Detailed Retrospective Chart Review from 2003 To The Present
  40. Correlation of SARS-CoV-2 viral burden with severity of disease in hospitalized patients with COVID-19
  41. Biorepository for Studies of the Immunopathogenesis of HIV Infection in Human Peripheral Blood cells in HIV-Infected and HIV-Uninfected Volunteers
  42. CSSC-001 Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19
  43. Phylogenetics and HIV networks in the Mid-Atlantic United States
  44. COVID-19 Online Symptom Tracker
  45. HIV Transmission Dynamics in Washington DC
  46. HIV Transmission Clusters and Transmitted Drug Resistance among HIV-positive individuals in the Washington DC metropolitan area
  47. Hospitalizations among PLWH
  48. Metropolitan Washington Women’s Interagency HIV Study (WIHS)
  49. Chronic kidney disease (CKD) among HIV-positive and HIV